Aethlon Medical, Inc. (OTCMKTS:AEMD) recently made a huge move up off its base around $0.10 to a high of $0.72 after the FDA approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®
After a dip to $0.17 lows AEMD has been moving up staedily since the Company announced on February 26 that the first patient enrolled in the Company’s FDA approved feasibility study has completed their full Hemopurifier® treatment protocol without any device-related adverse events. The study protocol, which is being administered at DaVita Med Center Dialysis in Houston, is enrolling ten chronic dialysis patients infected with Hepatitis C virus (HCV) to receive a six treatment protocol of Hemopurifier therapy. The Aethlon Hemopurifier is a first-in-class bio-filtration device that provides the broad-spectrum elimination of infectious viruses from the circulatory system of infected individuals.
Aethlon Medical, Inc. (OTCMKTS:AEMD) is a Medical Device Company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
The Aethlon Adaptive Dialysis-Like Affinity Platform Technology System (ADAPT™) is a medical device platform that converges single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without loss of essential blood components.
Recently AEMD successfully used their bio-filtration device, the Aethlon Hemopurifier® to treat a critically-ill Ebola-infected patient in Frankfurt, Germany. The patient was a Ugandan Doctor, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital, the patient was unconscious and suffering from multiple organ failure.
Recent date suggests a million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.
The Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
To Get the Inside Scoop on Aethlon, Subscribe via email Right Now.
The Company was recently featured in Time Magazine Naming The Aethlon Hemopurifier® One of the 25 Best Inventions of 2014 and AEMD announcing that the Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients.
On December 2 AEMD said the FDA has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. In the treatment of viral pathogens, the Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
The approved Ebola treatment protocol allows for an investigational study to be conducted at up to 10 U.S. clinical sites, and up to 20 U.S. subjects may be enrolled to receive the treatment protocol. Patients who meet the enrollment criteria will receive a daily six to eight hour administration of Hemopurifier® therapy until the point that Ebola viral load drops below 1000 copies/ml. The goal of the study is to standardize and evaluate the use of the Hemopurifier® as supportive care in the treatment of Ebola virus disease.
We have a Monster Pick Coming. Subscribe Right Now!
Over the past few months AEMD has transformed from unknown and illiquid at a dime to one of the top most traded stocks on the entire OTCBB recently hitting a high of $0.72 a share. The parabolic move comes on massive investor interest as Aethlon successfully treats a critically-ill Ebola-infected patient with the Aethlon Hemopurifier®.
After some consolidation AEMD is moving up in a hurry again after the Company said the FDA approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. Currently trading at a $78 million market valuation AEMD has captured the imaginations of small cap investors and is quickly building a loyal shareholder base that swears this one goes higher. AEMD is a stock to watch.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in AEMD either long or short and we have not been compensated for this article.